PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) recently announced that it has enrolled the first 143 patients in its pivotal Phase 3 REVERSE-IT trial for its lead product candidate …

PhaseBio Pharmaceuticals Achieves Enrollment Milestones Supporting Interim Analysis of REVERSE-IT Global Phase 3 Trial Read More

PhaseBio

PhaseBio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS) this week announced that the Investigational New Drug (IND) application for bentracimab submitted to the Center for Drug Evaluation (CDE) of the …

PhaseBio Pharmaceuticals and SFJ Pharmaceuticals Announce Approval of IND Application in China for Bentracimab Read More

PhaseBio

PhaseBio Highlights Real-World Bleeding, Surgery Data at American College of Cardiology’s Annual Scientific Session

MALVERN, PA — PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today highlighted real-world evidence presented over …

PhaseBio Highlights Real-World Bleeding, Surgery Data at American College of Cardiology’s Annual Scientific Session Read More